MedPath

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Phase 3
Completed
Conditions
Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
Registration Number
NCT00168740
Lead Sponsor
Biogen
Brief Summary

Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had a complete response and 70 patients had a partial response to rituximab. The median duration of response was 11.2 months.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Diagnosis of relapsed, low-grade or follicular B-cell lymphoma
  • CD20-positive lymphoma
  • Progressive, measurable disease
  • Sign informed consent
  • 3 weeks beyond standard therapy
  • Good performance status
  • Adequate hematologic, renal, and hepatic function
Exclusion Criteria
  • Chronic lymphocytic leukemia
  • Lesions greater than or equal to 10 cm in diameter
  • CNS lymphoma
  • AIDS-related lymphoma
  • Pleural effusions or ascites secondary to lymphoma
  • Active, opportunistic infection
  • Serious nonmalignant disease
  • Prior investigational therapies, including prior anti-CD20 therapy
  • Recent major surgery

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
overall response rate
Secondary Outcome Measures
NameTimeMethod
time to disease progression
progressive disease-free interval

Trial Locations

Locations (31)

University of Arkansas for Medical Sciences

🇺🇸

Little Rock, Arkansas, United States

City of Hope Natioal Medical Center

🇺🇸

Duarte, California, United States

Scripps Memorial Hospital

🇺🇸

La Jolla, California, United States

UCSD Stem Cell Laboratory

🇺🇸

La Jolla, California, United States

Hoag Hospital

🇺🇸

Newport Beach, California, United States

Sutter Cancer Center

🇺🇸

Sacramento, California, United States

Sidney Kimmel Cancer Center

🇺🇸

San Diego, California, United States

University of California, San Francisco

🇺🇸

San Francisco, California, United States

Stanford University Medical Center

🇺🇸

Stanford, California, United States

Kaiser Permanente Medical Center

🇺🇸

Vallejo, California, United States

Scroll for more (21 remaining)
University of Arkansas for Medical Sciences
🇺🇸Little Rock, Arkansas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.